Journal of Hepatology
Volume 48, Issue 6 , Pages 952-961, June 2008

Critical role of CD44 in hepatotoxin-mediated liver injury

  • Kiminori Kimura

      Affiliations

    • Department of Immunotherapeutics (Medinet), Graduate School of Medicine, The University of Tokyo, 1-3-7 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
    • Center for Emerging Infectious Diseases, Gifu University, Gifu-shi, Gifu 501-1194, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 3 5805 3161; fax: +81 3 5805 3164.
  • ,
  • Masahito Nagaki

      Affiliations

    • First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu-shi, Gifu 501-1194, Japan
  • ,
  • Kazuhiro Kakimi

      Affiliations

    • Department of Immunotherapeutics (Medinet), Graduate School of Medicine, The University of Tokyo, 1-3-7 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
  • ,
  • Masanao Saio

      Affiliations

    • Department of Immunopathology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu-shi, Gifu 501-1194, Japan
  • ,
  • Tomomi Saeki

      Affiliations

    • Center for Emerging Infectious Diseases, Gifu University, Gifu-shi, Gifu 501-1194, Japan
  • ,
  • Yumiko Okuda

      Affiliations

    • Center for Emerging Infectious Diseases, Gifu University, Gifu-shi, Gifu 501-1194, Japan
  • ,
  • Kazuo Kuwata

      Affiliations

    • Center for Emerging Infectious Diseases, Gifu University, Gifu-shi, Gifu 501-1194, Japan
  • ,
  • Hisataka Moriwaki

      Affiliations

    • First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu-shi, Gifu 501-1194, Japan

Received 16 August 2007; received in revised form 5 December 2007; accepted 3 January 2008. published online 11 March 2008.

Associate Editor: C. Trautwein

Background/Aims

Blocking of adhesion molecules is considered to be one of the therapeutic strategies inflammatory diseases, although it remains unclear whether this strategy is beneficial.

Methods

We used CD44-deficient mice to assess whether inhibition of CD44 could control liver injury caused by carbon tetrachloride (CCl4).

Results

CD44-deficient mice exhibited suppressed liver inflammation during the early phase (within 6h) after CCl4 injection due to reduced inflammatory cell infiltration and cytokine production, but showed severe liver inflammation with increased numbers of apoptotic hepatocytes at the late phase (after 12h). The induction of hepatocyte apoptosis was triggered by reduced NF-κB activity, which was induced by the low inflammatory cytokine concentrations. Furthermore, macrophages contributed to the induction of hepatocyte apoptosis, since neutralization by an anti-CD11b antibody significantly protected against hepatocyte apoptosis. Finally, we found that blocking of MIP-2 and TNF-α reduced hepatocyte apoptosis with decreased numbers of intrahepatic leukocytes and reduced inflammatory cytokine production.

Conclusions

These findings suggest that targeting of CD44 as a therapeutic approach for inflammatory liver diseases may require caution for particular immune systems in the liver.

Abbreviations: sALT, serum alanine aminotransferase, IHL, intrahepatic leukocyte, RPA, ribonuclease protection assay, CCl4, carbon tetrachloride, EMSA, electrophoretic mobility shift assay, FADD, Fas-associated death domain, TRADD, TNF receptor-associated death domain, HA, hyaluronic acid, MIP-2, macrophage inflammatory protein 2

Keywords: CD44, MIP-2, Liver inflammation, NF-κB, Macrophage

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors who have taken part in the research of this paper declared that they have a relationship with the manufacturers of the materials involved either in the past or present but they did not receive funding from the manufacturers to carry out their research.

PII: S0168-8278(08)00135-9

doi:10.1016/j.jhep.2008.01.033

Journal of Hepatology
Volume 48, Issue 6 , Pages 952-961, June 2008